Multibranched Lipid Complexes for Nuclease-Resistant Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nucleic acid medicines such as antisense oligonucleotides, siRNA, and miRNA face challenges with degradation by nucleases in vivo and low efficiency of incorporation into target cells, limiting their practical use.
Innovation Solution
A complex is formed by multibranched lipids binding to oligonucleotides through linkers, enhancing the suppressing activity of target gene expression without the need for gene transfection reagents, and improving delivery and accumulation in tissues like liver, skeletal muscles, and heart.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid medicines are used to suppress target gene expression, then gene silencing activity is achieved, but they are easily degraded by nucleases in vivo and have low efficiency of incorporation into target cells
Solution Approach 1:
The patent combines nucleic acid medicines with multibranched lipid structures to create composite conjugates. The lipid component provides stability against nuclease degradation while the nucleic acid portion maintains gene silencing activity, resolving the contradiction between reliability of gene suppression and stability in biological environments
Solution Approach 2:
The multibranched lipid acts as an intermediary carrier that protects the nucleic acid medicine from degradation by nucleases and facilitates its delivery into target cells. This mediator resolves the contradiction by providing both protection (stability) and delivery enhancement (incorporation efficiency)
2Stability of the object's composition
If chemical modification of nucleic acid is performed to improve stability, then resistance to nuclease degradation increases, but complexity of the nucleic acid structure increases
Solution Approach 1:
Instead of modifying the nucleic acid structure directly, the patent uses multibranched lipid molecules as intermediary carriers that provide stability and protection. This approach increases stability while avoiding the structural complexity that would result from extensive chemical modification of the nucleic acid itself
3Productivity
If gene transfection reagents are used to improve delivery efficiency, then incorporation into target cells increases, but complexity of the delivery system increases
Solution Approach 1:
The patent merges the delivery function and the therapeutic agent into a single integrated structure. The multibranched lipid conjugate simultaneously serves as both the delivery vehicle and the active therapeutic component, eliminating the need for separate gene transfection reagents and reducing overall system complexity
Solution Approach 2:
The multibranched lipid conjugate structure performs multiple functions: it protects the nucleic acid from degradation, facilitates cellular uptake, and delivers the therapeutic agent. This multi-functional design improves delivery efficiency while avoiding the complexity of multi-component delivery systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes enhance the suppressing activity of target gene expression and provide therapeutic or prophylactic effects by delivering nucleic acid medicines effectively to various tissues without using gene transfer reagents.
Implementation Method 1
a complex in which a multibranched lipid(s) binds to an oligonucleotide having suppressing activity of the target gene expression through a linker
Data Source
AI summary
The purpose of the present invention is to provide novel complexes that improve the effect of nucleic acid medicines. Provided is a complex in which a multibranched lipid(s) binds through a linker to a strand of an oligonucleotide comprising a nucleic acid medicine having suppressing activity of the target gene expression.